IRONWOOD PHARMACEUTICALS INC (IRWD) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does IRONWOOD PHARMACEUTICALS INC Do?
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts. IRONWOOD PHARMACEUTICALS INC (IRWD) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Thomas A. McCourt and employs approximately 220 people, headquartered in CAMBRIDGE, Massachusetts. With a market capitalization of $636M, IRWD is one of the notable companies in the Healthcare sector.
IRONWOOD PHARMACEUTICALS INC (IRWD) Stock Rating — Reduce (April 2026)
As of April 2026, IRONWOOD PHARMACEUTICALS INC receives a Reduce rating with a composite score of 38.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.IRWD ranks #2,595 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, IRONWOOD PHARMACEUTICALS INC ranks #337 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
IRWD Stock Price and 52-Week Range
IRONWOOD PHARMACEUTICALS INC (IRWD) currently trades at $3.54. The stock lost $0.06 (1.7%) in the most recent trading session. The 52-week high for IRWD is $5.78, which means the stock is currently trading -38.8% from its annual peak. The 52-week low is $0.53, putting the stock 571.6% above its annual trough. Recent trading volume was 1.2M shares, reflecting moderate market activity.
Is IRWD Overvalued or Undervalued? — Valuation Analysis
IRONWOOD PHARMACEUTICALS INC (IRWD) carries a value factor score of 74/100 in the Blank Capital model, suggesting the stock trades at a meaningful discount to its fundamental earning power. The trailing price-to-earnings ratio is 18.84x, compared to the Healthcare sector average of 23.63x — a discount of 20%. The price-to-sales ratio is 1.66x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, IRWD trades at 4.81x EV/EBITDA, versus 6.34x for the sector. The EV/EBIT multiple is 9.49x.
Based on these multiples, IRONWOOD PHARMACEUTICALS INC appears attractively valued relative to both its sector peers and the broader market. Value-oriented investors may find the current entry point compelling, particularly if the company's fundamental quality metrics also score well.
IRONWOOD PHARMACEUTICALS INC Profitability — ROE, Margins, and Quality Score
IRONWOOD PHARMACEUTICALS INC (IRWD) earns a quality factor score of 12/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -41.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 7.5% versus the sector average of -33.1%.
On a margin basis, IRONWOOD PHARMACEUTICALS INC reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is 18.1% (sector: -66.1%). Net profit margin stands at -6.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 29.3% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
IRWD Debt, Balance Sheet, and Financial Health
IRONWOOD PHARMACEUTICALS INC has a debt-to-equity ratio of -225.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 1.13x, suggesting adequate working capital coverage. Total debt on the balance sheet is $200M. Cash and equivalents stand at $140M.
IRWD has a beta of 0.67, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for IRONWOOD PHARMACEUTICALS INC is 27/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
IRONWOOD PHARMACEUTICALS INC Revenue and Earnings History — Quarterly Trend
In TTM 2026, IRONWOOD PHARMACEUTICALS INC reported revenue of $340M and earnings per share (EPS) of $0.15. Net income for the quarter was $30M. Gross margin was 100.0%. Operating income came in at $117M.
In FY 2025, IRONWOOD PHARMACEUTICALS INC reported revenue of $296M and earnings per share (EPS) of $0.15. Net income for the quarter was $24M. Revenue grew -15.7% year-over-year compared to FY 2024. Operating income came in at $99M.
In Q3 2025, IRONWOOD PHARMACEUTICALS INC reported revenue of $122M and earnings per share (EPS) of $0.25. Net income for the quarter was $40M. Revenue grew 33.3% year-over-year compared to Q3 2024. Operating income came in at $75M.
In Q2 2025, IRONWOOD PHARMACEUTICALS INC reported revenue of $85M and earnings per share (EPS) of $0.15. Net income for the quarter was $24M. Revenue grew -9.7% year-over-year compared to Q2 2024. Operating income came in at $45M.
Over the past 8 quarters, IRONWOOD PHARMACEUTICALS INC has demonstrated a growth trajectory, with revenue expanding from $94M to $340M. Investors analyzing IRWD stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
IRWD Dividend Yield and Income Analysis
IRONWOOD PHARMACEUTICALS INC (IRWD) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
IRWD Momentum and Technical Analysis Profile
IRONWOOD PHARMACEUTICALS INC (IRWD) has a momentum factor score of 65/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 24/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 20/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
IRWD vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, IRONWOOD PHARMACEUTICALS INC (IRWD) ranks #337 out of 838 stocks based on the Blank Capital composite score. This places IRWD in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing IRWD against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full IRWD vs S&P 500 (SPY) comparison to assess how IRONWOOD PHARMACEUTICALS INC stacks up against the broader market across all factor dimensions.
IRWD Next Earnings Date
No upcoming earnings date has been announced for IRONWOOD PHARMACEUTICALS INC (IRWD) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy IRWD? — Investment Thesis Summary
The quantitative profile for IRONWOOD PHARMACEUTICALS INC suggests caution. The quality score of 12/100 flags below-average profitability. The value score of 74/100 suggests attractive pricing relative to fundamentals. Price momentum is positive at 65/100, suggesting the trend favors buyers. High volatility (stability score 27/100) increases portfolio risk.
In summary, IRONWOOD PHARMACEUTICALS INC (IRWD) earns a Reduce rating with a composite score of 38.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on IRWD stock.
Related Resources for IRWD Investors
Explore more research and tools: IRWD vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare IRWD head-to-head with peers: IRWD vs AZN, IRWD vs SLGL, IRWD vs VMD.